Search Results

Avid Bioservices, Inc. announced that the company has achieved a Committed Badge from EcoVadis, one of the world’s most trusted providers of business sustainability ratings.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced that the company will participate at two upcoming investor conferences.

Avid Bioservices, Inc. today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization, announced the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029.

Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the third quarter and nine months ended January 31, 2024.

Avid Bioservices, Inc. (NASDAQ:CDMO) today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.

Cellipont Bioservices and Adva Biotechnology today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.

Avid Bioservices, Inc. announced that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Section 4 of the Securities Act of 1933, as amended.

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.

Cellipont Bioservices and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.